A global leading cause of death is cardiovascular disease (CVD), and this is often linked to a number of abnormalities in the arterial system. Numerous clinical, in vivo, and in vitro studies are ongoing to better understand various forms of CVD and to find ways to combat it. Although studying cells of the cardiovascular system in vitro has led to many discoveries, it is a challenge to study explanted cells because they do not grow well and lose specificity. However, researchers found that a combination of two transcription factors, MYCN and SOX17, can induce and indeﬁnitely expand cultured human arterial endothelial cell precursors that are derived from CD34+ stem cells.
The leading cause of death for U.S. citizens is cardiovascular disease, which affects nearly a third of the U.S. population. There is an active and dedicated search for effective therapies to address this serious medical issue. The use of immunotherapy approaches for a number of diseases and conditions is continuously gaining momentum. Included in this is the use of CD34+ stem cells from a patients’ own blood (autologously derived) to treat cardiovascular disease. CD34+ is derived from bone marrow and other tissue types. However, CD34+ stems cells are more widely known for their hematopoietic origin.